Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination

被引:288
作者
Narayanan, S. Priyadarshini [1 ]
Flores, Ana I. [1 ]
Wang, Feng [1 ]
Macklin, Wendy B. [1 ]
机构
[1] Cleveland Clin, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA
基金
美国国家卫生研究院;
关键词
PROMOTES OLIGODENDROCYTE DIFFERENTIATION; CELL LUNG-CANCER; PHASE-II TRIAL; TUBEROUS SCLEROSIS; IN-VIVO; TEMSIROLIMUS CCI-779; NERVOUS-SYSTEM; MESSENGER-RNA; MOUSE MODEL; S6; KINASE;
D O I
10.1523/JNEUROSCI.0232-09.2009
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Mammalian target of rapamycin (mTOR), a well known Akt substrate, regulates multiple cellular functions including cell growth and protein synthesis. The current study identifies a novel role of the Akt/mTOR pathway as a regulator of CNS myelination. Previously, we showed that overexpressing constitutively active Akt in oligodendrocytes in a transgenic mouse model induces enhanced CNS myelination, with no changes in the proliferation or survival of oligodendrocyte progenitor or mature cells. The present study focused on the signaling mechanisms regulating this hypermyelination induced by Akt. Activation of mTOR and its downstream substrates (p70S6 kinase and S6 ribosomal protein) was observed in Akt-overexpressing oligodendrocytes. When mTOR signaling was inhibited chronically in vivo with rapamycin starting at 6 weeks of age, the observed hypermyelination was reduced to approximately the amount of myelin seen in wild-type mice. mTOR inhibition had little impact on wild-type myelination between 6 and 12 weeks of age, suggesting that, in normal adults, myelination is relatively complete and is no longer regulated by mTOR signaling. However, when mTOR was chronically inhibited in young adult wild-type mice, myelination was reduced. These results suggest that, during active myelination, the major Akt signal regulating CNS myelination is the mTOR pathway.
引用
收藏
页码:6860 / 6870
页数:11
相关论文
共 50 条
[1]
Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation [J].
Alliouachene, Samira ;
Tuttle, Robyn L. ;
Boumard, Stephanie ;
Lapointe, Thomas ;
Berissi, Sophie ;
Germain, Stephane ;
Jaubert, Francis ;
Tosh, David ;
Birnbaum, Morris J. ;
Pende, Mario .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (11) :3629-3638
[2]
The two TORCs and Akt [J].
Bhaskar, Prashanth T. ;
Hay, Nissim .
DEVELOPMENTAL CELL, 2007, 12 (04) :487-502
[3]
Advances in protein kinase B signalling:: AKTion on multiple fronts [J].
Brazil, DP ;
Yang, ZZ ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (05) :233-242
[4]
Casaccia-Bonnefil P, 1999, DEVELOPMENT, V126, P4027
[5]
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation [J].
Choo, Andrew Y. ;
Yoon, Sang-Oh ;
Kim, Sang Gyun ;
Roux, Philippe P. ;
Blenis, John .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) :17414-17419
[6]
Inhibitors of the mammalian target of rapamycin [J].
Dancey, JE .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (03) :313-328
[7]
mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer [J].
Dann, Stephen G. ;
Selvaraj, Anand ;
Thomas, George .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (06) :252-259
[8]
PTEN signaling in brain: neuropathology and tumorigenesis [J].
Endersby, R. ;
Baker, S. J. .
ONCOGENE, 2008, 27 (41) :5416-5430
[9]
Rapamycin is a neuroprotective treatment for traumatic brain injury [J].
Erlich, S. ;
Alexandrovich, A. ;
Shohami, E. ;
Pinkas-Kramarski, R. .
NEUROBIOLOGY OF DISEASE, 2007, 26 (01) :86-93
[10]
Flores AI, 2000, J NEUROSCI, V20, P7622